Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation.
about
Fibroblast growth factor signaling in skeletal development and diseaseAntibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in miceSmall molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical applicationA place for precision medicine in bladder cancer: targeting the FGFRs.Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC)Affinity maturation of antibodies assisted by in silico modeling.Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder.FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancerDevelopment and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas.Analysis of multiple sarcoma expression datasets: implications for classification, oncogenic pathway activation and chemotherapy resistanceThe Fibroblast Growth Factor signaling pathwayThe FGF-1-specific single-chain antibody scFv1C9 effectively inhibits breast cancer tumour growth and metastasis.Histologic and genetic advances in refining the diagnosis of "undifferentiated pleomorphic sarcoma"FGFR4 role in epithelial-mesenchymal transition and its therapeutic value in colorectal cancerHigh-level expression, purification, and characterization of bifunctional ScFv-9R fusion protein.A putative OTU domain-containing protein 1 deubiquitinating enzyme is differentially expressed in thyroid cancer and identifies less-aggressive tumours.Development and Application of a Microfluidics-Based Panel in the Basal/Luminal Transcriptional Characterization of Archival Bladder CancersDevelopment of anti-CD47 single-chain variable fragment targeted magnetic nanoparticles for treatment of human bladder cancer.Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic targetNovel therapeutic targets in bladder cancer: mutation and expression of FGF receptors.The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancerThe role of fibroblast growth factors in tumor growthStrategies to improve drug delivery in bladder cancer therapy.Novel targeted agents for the treatment of bladder cancer: translating laboratory advances into clinical application.Exploiting Surface Plasmon Resonance (SPR) Technology for the Identification of Fibroblast Growth Factor-2 (FGF2) Antagonists Endowed with Antiangiogenic Activity.FGFR3 targeting strategies for achondroplasia.Animal models of urinary bladder cancer and their application to novel drug discovery.Inhibition of FGFR signaling by PD173074 improves antitumor immunity and impairs breast cancer metastasis.Achondroplasia: Development, pathogenesis, and therapy.Hypoxia regulates FGFR3 expression via HIF-1α and miR-100 and contributes to cell survival in non-muscle invasive bladder cancer.A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges.A novel single-chain variable fragment antibody against FGF-1 inhibits the growth of breast carcinoma cells by blocking the intracrine pathway of FGF-1.Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner.FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder.Identification of a GTP-bound Rho specific scFv molecular sensor by phage display selection.Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer.Production and Evaluation of Specific Single-Chain Antibodies against CTLA-4 for Cancer-Targeted Therapy.Overexpression of CDC91L1 (PIG-U) in bladder urothelial cell carcinoma: correlation with clinical variables and prognostic significance.
P2860
Q26798215-681F55A1-463B-45E1-9C98-AD1D226C61D2Q27654979-EC9CD28E-8ACF-4347-A0B3-08EE73AFDAC0Q27851612-9C4E6D0C-8E19-44BF-A065-4A660B4C1C49Q28079309-0C70FCE7-690D-43C1-9487-40790804AF95Q30249143-36F7CF50-549F-4B73-959D-52F69864D2F0Q30433431-983C8DC1-E405-4969-A460-8E8156F9C538Q30482656-81E46B1D-F652-452F-99FC-EAABC32304D3Q30857433-A5AC482B-A854-42C4-9C38-7F0960A90FBDQ33292711-9357E213-1B74-44F0-8CAF-8E5C93AE32B7Q33442189-347EE71E-D52C-41CA-A92E-C2380F97F6E5Q33549674-57CB13CA-E34B-496E-9E86-3B6F63167439Q34467171-6FC3481C-2784-4700-8DBC-58FA0D8975E6Q34571563-749B34F6-267A-45D7-96AB-4112BE442884Q34657369-6A6EDA0F-2072-4DA9-9081-EFC36E8C81A9Q34733972-A125254D-2386-4EB0-8719-F5AC4333ADECQ35092448-64F6F3AA-EDDD-4DE1-85FA-0E80188E734EQ35189765-82FC02A7-085B-4AD0-A391-06BAA1F080F7Q36192868-FD3F9FAD-093D-4A13-94F4-8E56FCAA27EAQ36276770-4D686994-78E6-4CBB-838F-D1936D6ED7A8Q36958930-1CFC0893-958D-4820-BCBD-744A63894BE1Q37074139-F837C222-0426-4ABF-B4D0-F2EDB098B232Q37389768-E8328423-CEBA-4E4F-A1B4-ACF8A580E78CQ37512303-7DCE45C6-D100-4AD6-918C-DCD4AB7C2CD1Q37523962-CE969054-750A-472B-A848-6D2DC74AAF50Q37770131-1C086ED6-6E84-445D-B70F-7E2600E1104CQ37997765-6D4BA9F7-FEFC-4EE5-A1E3-CB26E172F081Q38007566-38DD8CAD-8C8E-45EC-8A42-6BB90C3753ADQ38199547-F3798270-48D5-4CC4-85DD-DA20FF573031Q39036666-3C97FA57-B853-44DA-BD05-EB3A6F122BF3Q39041957-39C21502-4EB9-4062-B115-13F0F8BB3DA9Q39137839-A898626F-E7BD-401E-8B53-179CAFC4A77FQ39568069-936CE82A-54F7-479E-B442-D5A29CE802E2Q39584253-289539A7-D4A3-4F9E-A04E-8F559578B2BEQ39671016-CD9EFEB2-E2E5-4923-8560-FDB8EEE9C0D3Q39800120-61050250-D2EA-40C2-A428-B6313B60FF00Q43115752-78F9B215-0CE7-4AD7-A524-F5836FC89430Q43151828-4650AEFD-ABCE-49C5-95A3-76370C503300Q44643445-CDA81F19-8698-4C53-8E30-276B6BC274CCQ47151142-4840D912-4C08-4BC6-8864-12341CDF91C0Q53521507-F2948EEF-B2CA-434A-A83C-04787DFBBFFD
P2860
Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Targeting the extracellular do ...... inoma cell line proliferation.
@en
type
label
Targeting the extracellular do ...... inoma cell line proliferation.
@en
prefLabel
Targeting the extracellular do ...... inoma cell line proliferation.
@en
P2093
P50
P1476
Targeting the extracellular do ...... cinoma cell line proliferation
@en
P2093
Antonio Martínez
Gabriela Cifuentes
Pilar Saenz
P304
P356
10.1158/1078-0432.CCR-05-0282
P407
P577
2005-09-01T00:00:00Z